April 7, 2008-Giaconda Limited today announced that the European Patent Office (EPO) has granted its patent for its lead product, Myoconda, a combination therapy for patients with Crohn's Disease who are infected with MAP (Mycobacterium avium paratuberculosis).
The formal Decision to Grant from the EPO affords protection until April 2018 in all European member states and extension states, with patent number EP 98912149.6. The application was filed as part of a broader, international application under the Patent Cooperation Treaty (1970).
"The European Union is a key territory for MyocondaR," said Patrick McLean, Giaconda's Chief Executive Officer. "The protection of MyocondaR's intellectual property until 2018 in Europe provides an excellent window of opportunity for earnings. From the company's perspective, this milestone is another step in expanding our patent coverage and adding value to the IP portfolio."
No comments:
Post a Comment